Figure 1. Preclinical tools in the assessment of cardiotoxicity mediated by anticancer drug candidates.
CM indicates cardiomyocytes; hERG, human ether‐a‐go‐go–related Gene; hiPSC, human induced pluripotent stem cells; and hiPSC‐CM, human induced pluripotent stem cell–derived cardiomyocytes.